Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40ox% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia. (26th May 2010)

• Record Type: Journal Article
• Authors: Bibl, Mirko; Esselmann, Hermann; Lewczuk, Piotr; Trenkwalder, Claudia; Otto, Markus; Kornhuber, Johannes; Wiltfang, Jens; Mollenhauer, Brit
• Other Names: Parnetti Lucilla Academic Editor.
• Is Part Of: International journal of alzheimer's disease. Volume 2010(2010)
• Publication Date: 2010-05-26
• Subjects: Alzheimer's disease -- Periodicals; 616.831005
• DOI: 10.4061/2010/761571
• Languages: English
• ISSNs: 2090-8024

Abstract

Abstract : We studied the diagnostic value of CSF Aβ 42/tau versus low Aβ 1–42% and high Aβ 1–40 ox % levels for differential diagnosis of Alzheimer's disease (AD) and dementia with Lewy bodies (DLB), respectively. CSF of 45 patients with AD, 15 with DLB, 21 with Parkinson's disease dementia (PDD), and 40 nondemented disease controls (NDC) was analyzed by Aβ -SDS-PAGE/immunoblot and ELISAs (Aβ 42 and tau). Aβ 42/tau lacked specificity in discriminating AD from DLB and PDD. Best discriminating biomarkers were Aβ 1–42% and Aβ 1–40 ox % for AD and DLB, respectively. AD and DLB could be differentiated by both Aβ 1–42% and Aβ 1–40 ox % with an accuracy of 80% at minimum. Thus, we consider Aβ 1–42% and Aβ 1–40 ox % to be useful biomarkers for AD and DLB, respectively. We propose further studies on the integration of Aβ 1–42% and Aβ 1–40 ox % into conventional assay formats. Moreover, future studies should investigate the combination of Aβ 1–40 ox % and CSF alpha-synuclein for the diagnosis of DLB.